CoChat
Sign Up
Cited by 1,347Gut microbiota and healthMetabolomics and Mass Spectrometry StudiesAdipokines, Inflammation, and Metabolic Diseases

Gut microbiota-derived metabolites as central regulators in metabolic disorders

Open access
Agus, Allison, Clément, Karine, Sokol, Harry·2021·Gut
DOI 10.1136/gutjnl-2020-323071PMC PMC8108286
Open this paper in CoChat — free accountOpen PDF

Abstract

Metabolic disorders represent a growing worldwide health challenge due to their dramatically increasing prevalence. The gut microbiota is a crucial actor that can interact with the host by the production of a diverse reservoir of metabolites, from exogenous dietary substrates or endogenous host compounds. Metabolic disorders are associated with alterations in the composition and function of the gut microbiota. Specific classes of microbiota-derived metabolites, notably bile acids, short-chain fatty acids, branched-chain amino acids, trimethylamine N-oxide, tryptophan and indole derivatives, have been implicated in the pathogenesis of metabolic disorders. This review aims to define the key classes of microbiota-derived metabolites that are altered in metabolic diseases and their role in pathogenesis. They represent potential biomarkers for early diagnosis and prognosis as well as promising targets for the development of novel therapeutic tools for metabolic disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2020-323071

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Accumulating evidence suggests that the microbiota influences the regulation of appetite, eating behavior, common mental illnesses, immunity, and emotional states.

    “Accumulating evidence suggests that the microbiota influences the regulation of appetite, eating behavior, common mental illnesses, immunity, and even emotional states [89,90].”

    From The Seven Methods for the Evaluation of Nutritional Status—ABCDEFG: Narrative Review (2026) · cites this paper as [90]

    The Introduction (page unavailable) says the gut microbiota contributes to immune-system maturation. The section on microbiota-derived metabolites (page unavailable) links microbiota-modulated serotonin to feeding behaviour and satiety, supporting the appetite and eating-behaviour parts. Our copy does not address common mental illnesses or emotional states. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 100

  1. [3]Sittipo P, Shim J-W, Lee YK. Microbial metabolites determine host health and the status of some diseases. Int J Mol Sci 2019; 20: 5296. 10.3390/ijms20215296 PMC6862038 31653062 · DOI
  2. [4]Ni J, Wu GD, Albenberg L, et al. Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol 2017; 14: 573– 84. 10.1038/nrgastro.2017.88 28743984 PMC5880536 · DOI · Paper page
  3. [5]Alhinai EA, Walton GE, Commane DM. The role of the gut microbiota in colorectal cancer causation. Int J Mol Sci 2019; 20: 5295. 10.3390/ijms20215295 PMC6862640 31653078 · DOI
  4. [6]Ding R-X, Goh W-R, Wu R-N, et al. Revisit gut microbiota and its impact on human health and disease. J Food Drug Anal 2019; 27: 623– 31. 10.1016/j.jfda.2018.12.012 31324279 PMC9307029 · DOI
  5. [8]Dabke K, Hendrick G, Devkota S. The gut microbiome and metabolic syndrome. J Clin Invest 2019; 129: 4050– 7. 10.1172/JCI129194 31573550 PMC6763239 · DOI
  6. [9]Lamichhane S, Sen P, Dickens AM, et al. Gut metabolome meets microbiome: a methodological perspective to understand the relationship between host and microbe. Methods 2018; 149: 3– 12. 10.1016/j.ymeth.2018.04.029 29715508 · DOI
  7. [10]Tilg H, Zmora N, Adolph TE, et al. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol 2020; 20: 40– 54. 10.1038/s41577-019-0198-4 31388093 · DOI · Paper page
  8. [12]Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004; 101: 15718– 23. 10.1073/pnas.0407076101 15505215 PMC524219 · DOI · Paper page
  9. [13]Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027– 31. 10.1038/nature05414 17183312 · DOI · Paper page
  10. [14]Le Roy T, Llopis M, Lepage P, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2013; 62: 1787– 94. 10.1136/gutjnl-2012-303816 23197411 · DOI · Paper page
  11. [15]Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013; 341: 1241214. 10.1126/science.1241214 24009397 PMC3829625 · DOI · Paper page
  12. [16]Kimura I, Miyamoto J, Ohue-Kitano R, et al. Maternal gut microbiota in pregnancy influences offspring metabolic phenotype in mice. Science 2020; 367: eaaw8429. 10.1126/science.aaw8429 32108090 · DOI
  13. [18]Cotillard A, Kennedy SP, Kong LC, et al. Dietary intervention impact on gut microbial gene richness. Nature 2013; 500: 585– 8. 10.1038/nature12480 23985875 · DOI · Paper page
  14. [20]Aron-Wisnewsky J, Prifti E, Belda E, et al. Major microbiota dysbiosis in severe obesity: fate after bariatric surgery. Gut 2019; 68: 70– 82. 10.1136/gutjnl-2018-316103 29899081 PMC7143256 · DOI · Paper page
  15. [21]Chassaing B, Raja SM, Lewis JD, et al. Colonic microbiota Encroachment correlates with dysglycemia in humans. Cell Mol Gastroenterol Hepatol 2017; 4: 205– 21. 10.1016/j.jcmgh.2017.04.001 28649593 PMC5472192 · DOI
  16. [22]de Groot P, Scheithauer T, Bakker GJ, et al. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. Gut 2020; 69: 502– 12. 10.1136/gutjnl-2019-318320 31147381 PMC7034343 · DOI
  17. [24]Yu EW, Gao L, Stastka P, et al. Fecal microbiota transplantation for the improvement of metabolism in obesity: the FMT-TRIM double-blind placebo-controlled pilot trial. PLoS Med 2020; 17: e1003051. 10.1371/journal.pmed.1003051 32150549 PMC7062239 · DOI
  18. [25]Chen MX, Wang S-Y, Kuo C-H, et al. Metabolome analysis for investigating host-gut microbiota interactions. J Formos Med Assoc 2019; 118(Suppl 1): S10– 22. 10.1016/j.jfma.2018.09.007 30269936 · DOI
  19. [26]Monnerie S, Comte B, Ziegler D, et al. Metabolomic and lipidomic signatures of metabolic syndrome and its physiological components in adults: a systematic review. Sci Rep 2020; 10: 669. 10.1038/s41598-019-56909-7 31959772 PMC6971076 · DOI
  20. [27]Liu R, Hong J, Xu X, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med 2017; 23: 859– 68. 10.1038/nm.4358 28628112 · DOI · Paper page
  21. [28]Pedersen HK, Gudmundsdottir V, Nielsen HB, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 2016; 535: 376– 81. 10.1038/nature18646 27409811 · DOI · Paper page
  22. [29]Fiamoncini J, Rundle M, Gibbons H, et al. Plasma metabolome analysis identifies distinct human metabotypes in the postprandial state with different susceptibility to weight loss-mediated metabolic improvements. Faseb J 2018; 32: 5447– 58. 10.1096/fj.201800330R 29718708 · DOI
  23. [30]Surowiec I, Noordam R, Bennett K, et al. Metabolomic and lipidomic assessment of the metabolic syndrome in Dutch middle-aged individuals reveals novel biological signatures separating health and disease. Metabolomics 2019; 15: 23. 10.1007/s11306-019-1484-7 30830468 PMC6373335 · DOI
  24. [31]Org E, Blum Y, Kasela S, et al. Relationships between gut microbiota, plasma metabolites, and metabolic syndrome traits in the METSIM cohort. Genome Biol 2017; 18: 70. 10.1186/s13059-017-1194-2 28407784 PMC5390365 · DOI
  25. [32]Zhang C, Yin A, Li H, et al. Dietary modulation of gut microbiota contributes to alleviation of both genetic and simple obesity in children. EBioMedicine 2015; 2: 968– 84. 10.1016/j.ebiom.2015.07.007 26425705 PMC4563136 · DOI
  26. [33]Koh A, Molinaro A, Ståhlman M, et al. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. Cell 2018; 175: 947– 61. e17. 10.1016/j.cell.2018.09.055 30401435 · DOI · Paper page
  27. [34]Hoyles L, Fernández-Real J-M, Federici M, et al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med 2018; 24: 1070– 80. 10.1038/s41591-018-0061-3 29942096 PMC6140997 · DOI · Paper page
  28. [35]Ratajczak W, Rył A, Mizerski A, et al. Immunomodulatory potential of gut microbiome-derived short-chain fatty acids (SCFAs). Acta Biochim Pol 2019; 66: 1– 12. 10.18388/abp.2018_2648 30831575 · DOI
  29. [36]McGlone ER, Bloom SR. Bile acids and the metabolic syndrome. Ann Clin Biochem 2019; 56: 326– 37. 10.1177/0004563218817798 30453753 · DOI
  30. [38]Ma H, Patti ME. Bile acids, obesity, and the metabolic syndrome. Best Pract Res Clin Gastroenterol 2014; 28: 573– 83. 10.1016/j.bpg.2014.07.004 25194176 PMC4159616 · DOI
  31. [39]Ðanić M, Stanimirov B, Pavlović N, et al. Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome. Front Pharmacol 2018; 9: 1382. 10.3389/fphar.2018.01382 30559664 PMC6287190 · DOI
  32. [40]Kuno T, Hirayama-Kurogi M, Ito S, et al. Reduction in hepatic secondary bile acids caused by short-term antibiotic-induced dysbiosis decreases mouse serum glucose and triglyceride levels. Sci Rep 2018; 8: 1253. 10.1038/s41598-018-19545-1 29352187 PMC5775293 · DOI
  33. [41]Duboc H, Rajca S, Rainteau D, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 2013; 62: 531– 9. 10.1136/gutjnl-2012-302578 22993202 · DOI · Paper page
  34. [42]Parséus A, Sommer N, Sommer F, et al. Microbiota-induced obesity requires farnesoid X receptor. Gut 2017; 66: 429– 37. 10.1136/gutjnl-2015-310283 26740296 PMC5534765 · DOI
  35. [43]Lambert G, Amar MJA, Guo G, et al. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 2003; 278: 2563– 70. 10.1074/jbc.M209525200 12421815 · DOI
  36. [44]Prawitt J, Abdelkarim M, Stroeve JHM, et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 2011; 60: 1861– 71. 10.2337/db11-0030 21593203 PMC3121443 · DOI
  37. [45]Schmitt J, Kong B, Stieger B, et al. Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal. Liver Int 2015; 35: 1133– 44. 10.1111/liv.12456 25156247 PMC4146754 · DOI
  38. [48]Molinaro A, Wahlström A, Marschall H-U. Role of bile acids in metabolic control. Trends Endocrinol Metab 2018; 29: 31– 41. 10.1016/j.tem.2017.11.002 29195686 · DOI · Paper page
  39. [49]van Nierop FS, Scheltema MJ, Eggink HM, et al. Clinical relevance of the bile acid receptor TGR5 in metabolism. Lancet Diabetes Endocrinol 2017; 5: 224– 33. 10.1016/S2213-8587(16)30155-3 27639537 · DOI
  40. [50]Velazquez-Villegas LA, Perino A, Lemos V, et al. TGR5 signalling promotes mitochondrial fission and beige remodelling of white adipose tissue. Nat Commun 2018; 9: 245. 10.1038/s41467-017-02068-0 29339725 PMC5770450 · DOI · Paper page
  41. [51]Raimondi F, Santoro P, Barone MV, et al. Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation. Am J Physiol Gastrointest Liver Physiol 2008; 294: G906– 13. 10.1152/ajpgi.00043.2007 18239063 · DOI · Paper page
  42. [52]Suzuki T, Hara H. Dietary fat and bile juice, but not obesity, are responsible for the increase in small intestinal permeability induced through the suppression of tight junction protein expression in LETO and OLETF rats. Nutr Metab 2010; 7: 19. 10.1186/1743-7075-7-19 PMC2848226 20222989 · DOI
  43. [53]Stenman LK, Holma R, Korpela R. High-fat-induced intestinal permeability dysfunction associated with altered fecal bile acids. World J Gastroenterol 2012; 18: 923– 9. 10.3748/wjg.v18.i9.923 22408351 PMC3297051 · DOI · Paper page
  44. [55]Natividad JM, Lamas B, Pham HP, et al. Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice. Nat Commun 2018; 9: 2802. 10.1038/s41467-018-05249-7 30022049 PMC6052103 · DOI
  45. [56]Joyce SA, MacSharry J, Casey PG, et al. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Natl Acad Sci U S A 2014; 111: 7421– 6. 10.1073/pnas.1323599111 24799697 PMC4034235 · DOI · Paper page
  46. [57]Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 2016; 7: 189– 200. 10.1080/19490976.2015.1134082 26963409 PMC4939913 · DOI · Paper page
  47. [58]Kim CH. Microbiota or short-chain fatty acids: which regulates diabetes? Cell Mol Immunol 2018; 15: 88– 91. 10.1038/cmi.2017.57 28713163 PMC5811682 · DOI
  48. [59]Chambers ES, Morrison DJ, Frost G. Control of appetite and energy intake by SCFA: what are the potential underlying mechanisms? Proc Nutr Soc 2015; 74: 328– 36. 10.1017/S0029665114001657 25497601 · DOI
  49. [60]Hu J, Lin S, Zheng B, et al. Short-chain fatty acids in control of energy metabolism. Crit Rev Food Sci Nutr 2018; 58: 1243– 9. 10.1080/10408398.2016.1245650 27786539 · DOI
  50. [61]Priyadarshini M, Kotlo KU, Dudeja PK, et al. Role of short chain fatty acid receptors in intestinal physiology and pathophysiology. Compr Physiol 2018; 8: 1091– 115. 10.1002/cphy.c170050 29978895 PMC6058973 · DOI
  51. [62]Zhao L, Zhang F, Ding X, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science 2018; 359: 1151– 6. 10.1126/science.aao5774 29590046 · DOI · Paper page
  52. [63]Makki K, Deehan EC, Walter J, et al. The impact of dietary fiber on gut microbiota in host health and disease. Cell Host Microbe 2018; 23: 705– 15. 10.1016/j.chom.2018.05.012 29902436 · DOI · Paper page
  53. [64]De Vadder F, Kovatcheva-Datchary P, Goncalves D, et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014; 156: 84– 96. 10.1016/j.cell.2013.12.016 24412651 · DOI · Paper page
  54. [65]Zou J, Chassaing B, Singh V, et al. Fiber-Mediated Nourishment of gut microbiota protects against diet-induced obesity by restoring IL-22-mediated colonic health. Cell Host Microbe 2018; 23: 41– 53. 10.1016/j.chom.2017.11.003 29276170 PMC6005180 · DOI
  55. [67]Tajiri K, Shimizu Y. Branched-chain amino acids in liver diseases. Transl Gastroenterol Hepatol 2018; 3: 47. 10.21037/tgh.2018.07.06 30148232 PMC6088198 · DOI
  56. [68]Yoneshiro T, Wang Q, Tajima K, et al. BCAA catabolism in brown fat controls energy homeostasis through SLC25A44. Nature 2019; 572: 614– 9. 10.1038/s41586-019-1503-x 31435015 PMC6715529 · DOI
  57. [69]Yang Z, Huang S, Zou D, et al. Metabolic shifts and structural changes in the gut microbiota upon branched-chain amino acid supplementation in middle-aged mice. Amino Acids 2016; 48: 2731– 45. 10.1007/s00726-016-2308-y 27539648 · DOI · Paper page
  58. [70]Arany Z, Neinast M. Branched chain amino acids in metabolic disease. Curr Diab Rep 2018; 18: 76. 10.1007/s11892-018-1048-7 30112615 · DOI
  59. [71]Zhou M, Shao J, Wu C-Y, et al. Targeting BCAA catabolism to treat obesity-associated insulin resistance. Diabetes 2019; 68: 1730– 46. 10.2337/db18-0927 31167878 PMC6702639 · DOI
  60. [72]Dehghan P, Farhangi MA, Nikniaz L, et al. Gut microbiota-derived metabolite trimethylamine N-oxide (TMAO) potentially increases the risk of obesity in adults: an exploratory systematic review and dose-response meta- analysis. Obes Rev 2020; 21: e12993. 10.1111/obr.12993 32017391 · DOI
  61. [73]Shan Z, Sun T, Huang H, et al. Association between microbiota-dependent metabolite trimethylamine-N-oxide and type 2 diabetes. Am J Clin Nutr 2017; 106: 888– 94. 10.3945/ajcn.117.157107 28724646 · DOI · Paper page
  62. [74]Zhuang R, Ge X, Han L, et al. Gut microbe-generated metabolite trimethylamine N-oxide and the risk of diabetes: a systematic review and dose-response meta-analysis. Obes Rev 2019; 20: 883– 94. 10.1111/obr.12843 30868721 · DOI
  63. [75]Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013; 19: 576– 85. 10.1038/nm.3145 23563705 PMC3650111 · DOI · Paper page
  64. [78]Badawy AA-B. Kynurenine pathway and human systems. Exp Gerontol 2020; 129: 110770. 10.1016/j.exger.2019.110770 31704347 · DOI
  65. [79]Comai S, Bertazzo A, Brughera M, et al. Tryptophan in health and disease. Adv Clin Chem 2020; 95: 165– 218. 10.1016/bs.acc.2019.08.005 32122523 · DOI
  66. [80]Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 2015; 161: 264– 76. 10.1016/j.cell.2015.02.047 25860609 PMC4393509 · DOI · Paper page
  67. [81]Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2020; 17: 223– 37. 10.1038/s41575-019-0258-z 32076145 · DOI · Paper page
  68. [83]Natividad JM, Agus A, Planchais J, et al. Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome. Cell Metab 2018; 28: 737– 49. 10.1016/j.cmet.2018.07.001 30057068 · DOI · Paper page
  69. [85]Beaumont M, Neyrinck AM, Olivares M, et al. The gut microbiota metabolite indole alleviates liver inflammation in mice. Faseb J 2018: fj201800544: 6681– 93. 10.1096/fj.201800544 29906245 PMC6219839 · DOI
  70. [86]Postal BG, Ghezzal S, Aguanno D, et al. AhR activation defends gut barrier integrity against damage occurring in obesity. Mol Metab 2020; 39: 101007. 10.1016/j.molmet.2020.101007 32360426 PMC7267728 · DOI
  71. [87]Mallmann NH, Lima ES, Lalwani P. Dysregulation of tryptophan catabolism in metabolic syndrome. Metab Syndr Relat Disord 2018; 16: 135– 42. 10.1089/met.2017.0097 29406815 · DOI
  72. [88]Moyer BJ, Rojas IY, Kerley-Hamilton JS, et al. Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. model for AhR activation by kynurenine via oxidized-LDL, TLR2/4, TGFβ, and IDO1. Toxicol Appl Pharmacol 2016; 300: 13– 24. 10.1016/j.taap.2016.03.011 27020609 PMC4851598 · DOI
  73. [89]Laurans L, Venteclef N, Haddad Y, et al. Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. Nat Med 2018; 24: 1113– 20. 10.1038/s41591-018-0060-4 29942089 · DOI
  74. [90]Liu J-J, Movassat J, Portha B. Emerging role for kynurenines in metabolic pathologies. Curr Opin Clin Nutr Metab Care 2019; 22: 82– 90. 10.1097/MCO.0000000000000529 30407222 · DOI
  75. [92]Young RL, Lumsden AL, Keating DJ. Gut serotonin is a regulator of obesity and metabolism. Gastroenterology 2015; 149: 253– 5. 10.1053/j.gastro.2015.05.020 26025313 · DOI · Paper page
  76. [93]Crane JD, Palanivel R, Mottillo EP, et al. Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis. Nat Med 2015; 21: 166– 72. 10.1038/nm.3766 25485911 PMC5647161 · DOI
  77. [94]Fukui M, Tanaka M, Toda H, et al. High plasma 5-hydroxyindole-3-acetic acid concentrations in subjects with metabolic syndrome. Diabetes Care 2012; 35: 163– 7. 10.2337/dc11-1619 22100965 PMC3241327 · DOI
  78. [95]Molinaro A, Bel Lassen P, Henricsson M, et al. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology. Nat Commun 2020; 11: 5881. 10.1038/s41467-020-19589-w 33208748 PMC7676231 · DOI
  79. [96]Allegretti JR, Kassam Z, Mullish BH, et al. Effects of fecal microbiota transplantation with oral capsules in obese patients. Clin Gastroenterol Hepatol 2020; 18: 855– 63. 10.1016/j.cgh.2019.07.006 31301451 · DOI
  80. [97]Dao MC, Everard A, Aron-Wisnewsky J, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 2016; 65: 426– 36. 10.1136/gutjnl-2014-308778 26100928 · DOI · Paper page
  81. [98]Zhang T, Li Q, Cheng L, et al. Akkermansia muciniphila is a promising probiotic. Microb Biotechnol 2019; 12: 1109– 25. 10.1111/1751-7915.13410 31006995 PMC6801136 · DOI · Paper page
  82. [99]Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med 2019; 25: 1096– 103. 10.1038/s41591-019-0495-2 31263284 PMC6699990 · DOI · Paper page
  83. [100]Bian X, Wu W, Yang L, et al. Administration of Akkermansia muciniphila ameliorates dextran sulfate sodium-induced ulcerative colitis in mice. Front Microbiol 2019; 10: 2259. 10.3389/fmicb.2019.02259 31632373 PMC6779789 · DOI
  84. [101]Wu F, Guo X, Zhang M, et al. An Akkermansia muciniphila subtype alleviates high-fat diet-induced metabolic disorders and inhibits the neurodegenerative process in mice. Anaerobe 2020; 61: 102138. 10.1016/j.anaerobe.2019.102138 31830598 · DOI
  85. [102]Lazarević S, Đanić M, Goločorbin-Kon S, et al. Semisynthetic bile acids: a new therapeutic option for metabolic syndrome. Pharmacol Res 2019; 146: 104333. 10.1016/j.phrs.2019.104333 31254667 · DOI
  86. [103]Ratziu V, Sanyal AJ, Loomba R, et al. Regenerate: design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials 2019; 84: 105803. 10.1016/j.cct.2019.06.017 31260793 · DOI
  87. [104]Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 2006; 103: 1006– 11. 10.1073/pnas.0506982103 16410358 PMC1347977 · DOI
  88. [105]Cao Y, Xiao Y, Zhou K, et al. FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection. Am J Physiol Gastrointest Liver Physiol 2019; 317: G108– 15. 10.1152/ajpgi.00356.2017 30920307 · DOI
  89. [106]Pathak P, Xie C, Nichols RG, et al. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. Hepatology 2018; 68: 1574– 88. 10.1002/hep.29857 29486523 PMC6111007 · DOI · Paper page
  90. [107]Huang S, Ma S, Ning M, et al. TGR5 agonist ameliorates insulin resistance in the skeletal muscles and improves glucose homeostasis in diabetic mice. Metabolism 2019; 99: 45– 56. 10.1016/j.metabol.2019.07.003 31295453 · DOI
  91. [108]Chambers ES, Byrne CS, Morrison DJ, et al. Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised cross-over trial. Gut 2019; 68: 1430– 8. 10.1136/gutjnl-2019-318424 30971437 PMC6691855 · DOI · Paper page
  92. [109]den Besten G, Bleeker A, Gerding A, et al. Short-Chain fatty acids protect against high-fat diet-induced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation. Diabetes 2015; 64: 2398– 408. 10.2337/db14-1213 25695945 · DOI · Paper page
  93. [110]Fang W, Xue H, Chen X, et al. Supplementation with sodium butyrate modulates the composition of the gut microbiota and ameliorates high-fat diet-induced obesity in mice. J Nutr 2019; 149: 747– 54. 10.1093/jn/nxy324 31004166 · DOI
  94. [111]Nagasumi K, Esaki R, Iwachidow K, et al. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 2009; 58: 1067– 76. 10.2337/db08-1233 19401434 PMC2671040 · DOI
  95. [112]Schmidt J, Smith NJ, Christiansen E, et al. Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem 2011; 286: 10628– 40. 10.1074/jbc.M110.210872 21220428 PMC3060514 · DOI
  96. [113]Hudson BD, Due-Hansen ME, Christiansen E, et al. Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. J Biol Chem 2013; 288: 17296– 312. 10.1074/jbc.M113.455337 23589301 PMC3682533 · DOI
  97. [114]Milligan G, Alvarez-Curto E, Hudson BD, et al. FFA4/GPR120: pharmacology and therapeutic opportunities. Trends Pharmacol Sci 2017; 38: 809– 21. 10.1016/j.tips.2017.06.006 28734639 PMC5582618 · DOI
  98. [115]Cummings NE, Williams EM, Kasza I, et al. Restoration of metabolic health by decreased consumption of branched-chain amino acids. J Physiol 2018; 596: 623– 45. 10.1113/JP275075 29266268 PMC5813603 · DOI
  99. [116]Luo L, Aubrecht J, Li D, et al. Assessment of serum bile acid profiles as biomarkers of liver injury and liver disease in humans. PLoS One 2018; 13: e0193824. 10.1371/journal.pone.0193824 29513725 PMC5841799 · DOI
  100. [117]Ma Z, Wang X, Yin P, et al. Serum metabolome and targeted bile acid profiling reveals potential novel biomarkers for drug-induced liver injury. Medicine 2019; 98: e16717. 10.1097/MD.0000000000016717 31374067 PMC6708818 · DOI

Cited by

Sorted by citations

Authors
Agus, A., Clément, K., & Sokol, H.
Affiliations
  • AgroParisTech (FR)
  • Inserm (FR)
Corresponding author
Sokol, Harry
ORCID
Venue
Gut
Publisher
BMJ
Published
2020-12-03
Volume
70
Issue
6
Pages
1174-1182
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
DOI
10.1136/gutjnl-2020-323071
PMC
PMC8108286
OpenAlex
W3107083588
Cited by
1,347
References
17
Citations by year
2026: 262 · 2025: 283 · 2024: 303 · 2023: 252 · 2022: 181 · 2021: 63 · 2020: 1 · 2012: 1
FWCI
11.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Gut (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • HAL (submittedVersion)
Funders
H2020 European Research Council (ERC-2016-StG-71577)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
Keywords
gut microbiota, gut microbiota metabolites, metabolic disorders, bile acids, short-chain fatty acids, branched-chain amino acids, trimethylamine N-oxide, tryptophan metabolites, indole derivatives, pathogenesis, biomarkers, therapeutic target
MeSH terms
Gastrointestinal Microbiome, Host Microbial Interactions, Animals, Bile Acids and Salts, Fatty Acids, Volatile, Humans, Indoles, Metabolic Diseases, Methylamines, Tryptophan, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review